Macrolide use and the risk of vascular disease in HIV-infected men in the multicenter AIDS cohort study

Sexual Health

Volumn 4, Issue 2, 2007, Pages 111-119

  Woolley, Ian J ^a   Li, Xiuhong ^b   Jacobson, Lisa P ^b   Palella, Frank J ^c   Ostergaard, Lars ^d  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

HIV; Macrolide; Myocardial infarct; Vascular event

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; STEROID; SULFANILAMIDE DERIVATIVE; TETRACYCLINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SMOKING; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CORONARY THROMBOSIS; HIV INFECTIONS; HUMANS; MACROLIDES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VASCULAR DISEASES;

EID: 34249325845     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH06052     Document Type: Article

References (43)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhreh J, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60. doi: 10.1056/NEJM199803263381301
2. Passalaris JD, Sepkowitz KA, GlesbyMJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787-97. doi: 10.1086/313995
3. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 18: 329-33.
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86. doi: 10.1097/00002030- 200311210-00010
5. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-7.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70. doi: 10.1097/00002030-199907090-00001
7. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9. doi: 10.1086/317541
8. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003. doi: 10.1056/NEJMoa030218
9. Muller F, Svardal AM, Aukrust P, Berge RK, Ueland PM, Froland SS. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection. Am J Clin Nutr 1996; 63: 242-8.
10. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15: 15-24. doi: 10.1089/108729101460065
11. Blasi F, Cosentini R, Clerici Schoeller M, Lupo A, Allegra L. Chlamydia pneumoniae seroprevalence in imunocompetent and immunocompromised populations in Milan. Thorax 1993; 48: 1261-3.
12. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebocontrolled trial. Lancet 2001; 357: 2085-9. doi: 10.1016/S0140-6736(00)05181-3
13. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60.
14. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, et al. Randomised placebo controlled multicentre trial to assess short termclarithromycin for patients with stable coronary heart disease: CLARICOR trial. CLARICOR Trial Group. BMJ 2006; 332: 22-7. doi: 10.1136/bmj.38666.653600.55
15. Ostergaard L, Sorensen HT, Lindholt J, Sorensen TE, Pedersen L, Eriksen T, et al. Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study. J Infect Dis 2001; 183: 1625-30. doi: 10.1086/320718
16. Pilote L, Green L, Joseph L, Richard H, Eisenberg MJ. Antibiotics against Chlamydia pneumoniae and prognosis after acute myocardial infarction. Am Heart J 2002; 143: 294-300. doi: 10.1067/mhj.2002.120296
17. Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis 2002; 185: 1631-6. doi: 10.1086/340575
18. Chmiel JS, Detels R, Kaslow RA, Van Raden M, Kingsley LA, Brookmeyer R. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987; 126: 568-77.
19. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study: retention after 91/2 years. Am J Epidemiol 1995; 142: 323-30.
20. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville: AIDSinfo. Available online at: http://hivatis.org [verified 11 April 2007]
21. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. J Am Med Assoc 1998; 280: 1497-503. doi: 10.1001/jama.280.17.1497
22. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997; 145: 72-80.
23. Kaplan JE, Masur H, Holmes KK, McNeil MM, Schonberger LB, Navin TR, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995; 21: S1-11.
24. Miserez AR, Muller PY, Barella L, SchwietertM, Erb P, Vernazza PL, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. Swiss HIV Cohort Study. AIDS 2001; 15: 2045-9. doi: 10.1097/00002030-200110190-00020
25. Manuel O, Thiebaut R, Darioli R, Tarr PE. Treatment of dyslipidaemia in HIV-infected persons. Expert Opin Pharmacother 2005; 6: 1619-45. doi: 10.1517/14656566.6.10.1619
26. Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49: 283-90. doi: 10.1016/j.jinf.2003. 09.006
27. van't Wout AB, Swain JV, Schindler M, Rao U, Pathmajeyan MS, Mullins JI, et al. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol 2005; 79: 10053-8. doi: 10.1128/JVI.79.15.10053-10058.2005
28. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, et al. HIV infection and high density lipoprotein: the effect of the disease versus the effect of treatment. Metabolism 2006; 55: 90-5. doi: 10.1016/j.metabol. 2005.07.012
29. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6: 114-21. doi: 10.1111/j.1468-1293.2005. 00273.x
30. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82. doi: 10.1001/jama.289.22.2978
31. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165: 1179-84. doi: 10.1001/archinte.165.10.1179
32. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8. doi: 10.1016/S0140-6736(02) 11672-2
33. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-10. doi: 10.1056/NEJMoa022048
34. Constans J, Marchand JM, Conri C, Peuchant E, Seigneur M, Risp P, et al. Asymptomatic atherosclerosis in HIV positive patients: A casecontrol ultrasound study. Ann Med 1995; 27: 683-5.
35. Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 2004; 24: 338-43. doi: 10.1592/phco.24.4.338.33181
36. Wells BJ, Mainous AG 3rd, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004; 164: 2156-61. doi: 10.1001/archinte.164. 19.2156
37. Lim LL, Kotsanas D, Ostergaard L, Woolley I. The use of antibiotics as secondary prevention for cardiac events. Pharmacotherapy 2004; 24: 1652-3. doi: 10.1592/phco.24.16.1652.50944
38. Tositti G, Rassu M, Fabris P, Giordani M, Cazzavillan S, Reatto P, et al. Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile. HIV Med 2005; 6: 27-32. doi: 10.1111/j.1468-1293.2005.00261.x
39. Woolley IJ, Larsen M, Jones S, Gahan ME, Jasenko I, Johnsen SP, et al. Ostergaard Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-gamma assay, serology and PCR. Clin Microbiol Infect 2004; 10: 820-5. doi: 10.1111/j.1198-743X. 2004.00952.x
40. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5. doi: 10.1001/jama.285.19.2481
41. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62: 499-506. doi: 10.1016/j.mehy.2003.12.014
42. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45. doi: 10.1002/1529-0131(200112)44:12<2737::AIDART460> 3.0.CO;2-#
43. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21. doi: 10.1093/jac/dkh519